|
1 Indications And Usage Lymepak Is A Tetracycline Class Drug Indicated For The Treatment Of Early Lyme Disease (As Evidenced By Erythema Migrans) Due To Borrelia Burgdorferi In Adults And Pediatric Patients 8 Years Of Age And Older Weighing 45 Kg And Above. ( 1.1 ) To Reduce The Development Of Drug-Resistant Bacteria And Maintain The Effectiveness Of Lymepak And Other Antibacterial Drugs, Lymepak Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Bacteria ( 1.2 ). 1.1 Early Lyme Disease Lymepak Is Indicated For The Treatment Of Early Lyme Disease (As Evidenced By Erythema Migrans) Due To Borrelia Burgdorferi In Adults And Pediatric Patients 8 Years Of Age And Older Weighing 45 Kg And Above. 1.2 Usage To Reduce The Development Of Drug-Resistant Bacteria And Maintain The Effectiveness Of Lymepak And Other Antibacterial Drugs, Lymepak Should Be Used Only To Treat Or Prevent Infections That Are Proven Or Strongly Suspected To Be Caused By Susceptible Bacteria. When Culture And Susceptibility Information Are Available, They Should Be Considered In Selecting Or Modifying Antibacterial Therapy. In The Absence Of Such Data, Local Epidemiology And Susceptibility Patterns May Contribute To The Empiric Selection Of Therapy.
|